Hogarty MD - Search Results

1

Mutations in PIK3CA are infrequent in neuroblastoma.

Dam V, Morgan BT, Mazanek P, Hogarty MD. Dam V, et al. Among authors: hogarty md. BMC Cancer. 2006 Jul 5;6:177. doi: 10.1186/1471-2407-6-177. BMC Cancer. 2006. PMID: 16822308 Free PMC article.

2

Mononucleotide repeat instability is infrequent in neuroblastoma.

Hogarty MD, White PS, Sulman EP, Brodeur GM. Hogarty MD, et al. Cancer Genet Cytogenet. 1998 Oct 15;106(2):140-3. doi: 10.1016/s0165-4608(98)00050-8. Cancer Genet Cytogenet. 1998. PMID: 9797779

3

Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36 or at other tumor suppressor loci in neuroblastoma.

Thompson PM, Maris JM, Hogarty MD, Seeger RC, Reynolds CP, Brodeur GM, White PS. Thompson PM, et al. Among authors: hogarty md. Cancer Res. 2001 Jan 15;61(2):679-86. Cancer Res. 2001. PMID: 11212268

4

Comprehensive analysis of chromosome 1p deletions in neuroblastoma.

Maris JM, Guo C, Blake D, White PS, Hogarty MD, Thompson PM, Rajalingam V, Gerbing R, Stram DO, Matthay KK, Seeger RC, Brodeur GM. Maris JM, et al. Among authors: hogarty md. Med Pediatr Oncol. 2001 Jan;36(1):32-6. doi: 10.1002/1096-911X(20010101)36:1<32::AID-MPO1009>3.0.CO;2-0. Med Pediatr Oncol. 2001. PMID: 11464900

5

No evidence for the presence of an imprinted neuroblastoma suppressor gene within chromosome sub-band 1p36.3.

Hogarty MD, Winter CL, Liu X, Guo C, White PS, Look AT, Brodeur GM, Maris JM. Hogarty MD, et al. Cancer Res. 2002 Nov 15;62(22):6481-4. Cancer Res. 2002. PMID: 12438240

6

ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.

Wang Q, Hii G, Shusterman S, Mosse Y, Winter CL, Guo C, Zhao H, Rappaport E, Hogarty MD, Maris JM. Wang Q, et al. Among authors: hogarty md. Cancer Res. 2003 Apr 1;63(7):1631-5. Cancer Res. 2003. PMID: 12670915

7

The requirement for evasion of programmed cell death in neuroblastomas with MYCN amplification.

Hogarty MD. Hogarty MD. Cancer Lett. 2003 Jul 18;197(1-2):173-9. doi: 10.1016/s0304-3835(03)00103-4. Cancer Lett. 2003. PMID: 12880978 Review.

8

Targeting programmed cell death pathways with experimental therapeutics: opportunities in high-risk neuroblastoma.

Goldsmith KC, Hogarty MD. Goldsmith KC, et al. Among authors: hogarty md. Cancer Lett. 2005 Oct 18;228(1-2):133-41. doi: 10.1016/j.canlet.2005.01.048. Cancer Lett. 2005. PMID: 15927359 Review.

9

BH3 peptidomimetics potently activate apoptosis and demonstrate single agent efficacy in neuroblastoma.

Goldsmith KC, Liu X, Dam V, Morgan BT, Shabbout M, Cnaan A, Letai A, Korsmeyer SJ, Hogarty MD. Goldsmith KC, et al. Among authors: hogarty md. Oncogene. 2006 Aug 3;25(33):4525-33. doi: 10.1038/sj.onc.1209489. Epub 2006 Mar 27. Oncogene. 2006. PMID: 16568093

10

Neuroblastoma.

Maris JM, Hogarty MD, Bagatell R, Cohn SL. Maris JM, et al. Among authors: hogarty md. Lancet. 2007 Jun 23;369(9579):2106-20. doi: 10.1016/S0140-6736(07)60983-0. Lancet. 2007. PMID: 17586306 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

127 results

Search Page